Answers are grounded in this paper and cite their sources.
BACKGROUND: Eltrombopag is an established second-line therapy for children with persistent or chronic immune thrombocytopenia (ITP), but treatment-free remission after discontinuation and its relationship with treatment timing remain insufficiently defined. We evaluated eltrombopag outcomes, focusing on initiation timing and time to treatment-free remission. PROCEDURE: /L for at least six consecutive months without ITP-directed treatment and without bleeding or other clinical symptoms. Persistent- versus chronic-phase initiation was compared using Kaplan-Meier analysis and the log-rank test. RESULTS: Overall, platelet response was achieved in 36/41 patients (88%), sustained platelet response in 23/41 (56%), and treatment-free remission in 14/41 (34%). In the 40-patient timing cohort, time to treatment-free remission was shorter with persistent-phase initiation than with chronic-phase initiation (log-rank p = 0.027); Kaplan-Meier estimated median times were 28 and 78 months, respectively. Among patients achieving treatment-free remission, a longer diagnosis-to-eltrombopag interval was associated with a longer eltrombopag-to-remission interval (rho = 0.543, p = 0.045, n = 14). Adverse events occurred in 8/41 patients (20%), with no permanent discontinuations. CONCLUSIONS: Eltrombopag was associated with high platelet response rates and treatment-free remission in approximately one-third of treated children. Persistent-phase initiation was associated with shorter time to treatment-free remission than chronic-phase initiation. Prospective multicenter studies are needed to determine whether earlier eltrombopag initiation is associated with a higher likelihood of, or shorter time to, treatment-free remission.
No takes yet. Share an insight, caveat, or question.
İzmir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: